1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program;McLaughlin;J Clin Oncol,1998
2. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment;Davis;J Clin Oncol,2000
3. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma;Hainsworth;Blood,2000
4. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma;Hainsworth;Proc Am Soc Clin Oncol,2001
5. Rituximab as first-line treatment of follicular lymphoma patients with a low tumor burden. Preliminary results of a phase II trial;Solal-Celigny;Ann Oncol,1999